Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

about

Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.

P2860

Q42660148-3EBC812A-50B0-4B72-BB1C-EED17702903F Q55240690-3F86E93F-3FD2-49E2-AC0B-0FD06B7137ED

P2860

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Item

http://www.wikidata.org/entity/Q42660162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@en

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@nl

type

Item

label

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@en

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@nl

prefLabel

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@en

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@nl

P1476

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

@en

P2093

Anna Otte

http://www.w3.org/2001/XMLSchema#string

Katja Klausz

http://www.w3.org/2001/XMLSchema#string

Matthias Peipp

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the murine unglycosylated IgG1 Fc fragment

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Complement is activated by IgG hexamers assembled at the cell surface.

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

P304

327-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000479980

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Kellner

Elisa Cappuzzello

P577

2017-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29070978

http://www.w3.org/2001/XMLSchema#string

P932

5649276

http://www.w3.org/2001/XMLSchema#string

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

about

P2860

P2860

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932